Cargando…

Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study

OBJECTIVE: The objective of this study is to determine the prevalence and predictors of sickness absence (SA) and disability pension (DP) in women with metastatic breast cancer (mBC). METHODS: Data were obtained from Swedish registers concerning 1,240 adult women diagnosed 1997–2011 with mBC, from 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Altena, Renske, Gernaat, Sofie A. M., Wilking, Ulla, Kiani, Narsis A., Johnsson, Aina, Hedayati, Elham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541357/
https://www.ncbi.nlm.nih.gov/pubmed/35621269
http://dx.doi.org/10.1111/ecc.13626
_version_ 1784803906827583488
author Altena, Renske
Gernaat, Sofie A. M.
Wilking, Ulla
Kiani, Narsis A.
Johnsson, Aina
Hedayati, Elham
author_facet Altena, Renske
Gernaat, Sofie A. M.
Wilking, Ulla
Kiani, Narsis A.
Johnsson, Aina
Hedayati, Elham
author_sort Altena, Renske
collection PubMed
description OBJECTIVE: The objective of this study is to determine the prevalence and predictors of sickness absence (SA) and disability pension (DP) in women with metastatic breast cancer (mBC). METHODS: Data were obtained from Swedish registers concerning 1,240 adult women diagnosed 1997–2011 with mBC, from 1 year before (y−1) to 2 (y1) and 2 (y2) years after diagnosis. SA and DP prevalence was calculated. Odds ratios (AOR) were determined for factors associated with using long‐term (SA > 180 days or DP > 0 days) sickness benefits. RESULTS: Prevalence of SA and DP was 56.0% and 24.8% during y−1, 69.9% and 28.9% during y1, and 64.0% and 34.7% during y2, respectively. Odds of using long‐term sickness benefits were higher y1 and y2 in patients using long‐term sickness benefits the year before diagnosis (AOR = 3.82, 95% CI 2.91–5.02; AOR = 4.31, 95% CI 2.96–6.29, respectively) and y2 in patients with mBC diagnosis 1997–2000 (AOR = 1.84, 95% CI 1.10–3.08) and using long‐term sickness benefits the year after diagnosis (AOR = 22.10, 95% CI 14.33–34.22). CONCLUSIONS: The prevalence of sickness benefit utilisation was high and increased after mBC diagnosis, particularly for patients using long‐term sickness benefits prior to diagnosis. Additional study is needed to determine factors that might reduce the need for sickness benefits and enhance work ability in these patients.
format Online
Article
Text
id pubmed-9541357
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95413572022-10-14 Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study Altena, Renske Gernaat, Sofie A. M. Wilking, Ulla Kiani, Narsis A. Johnsson, Aina Hedayati, Elham Eur J Cancer Care (Engl) Original Articles OBJECTIVE: The objective of this study is to determine the prevalence and predictors of sickness absence (SA) and disability pension (DP) in women with metastatic breast cancer (mBC). METHODS: Data were obtained from Swedish registers concerning 1,240 adult women diagnosed 1997–2011 with mBC, from 1 year before (y−1) to 2 (y1) and 2 (y2) years after diagnosis. SA and DP prevalence was calculated. Odds ratios (AOR) were determined for factors associated with using long‐term (SA > 180 days or DP > 0 days) sickness benefits. RESULTS: Prevalence of SA and DP was 56.0% and 24.8% during y−1, 69.9% and 28.9% during y1, and 64.0% and 34.7% during y2, respectively. Odds of using long‐term sickness benefits were higher y1 and y2 in patients using long‐term sickness benefits the year before diagnosis (AOR = 3.82, 95% CI 2.91–5.02; AOR = 4.31, 95% CI 2.96–6.29, respectively) and y2 in patients with mBC diagnosis 1997–2000 (AOR = 1.84, 95% CI 1.10–3.08) and using long‐term sickness benefits the year after diagnosis (AOR = 22.10, 95% CI 14.33–34.22). CONCLUSIONS: The prevalence of sickness benefit utilisation was high and increased after mBC diagnosis, particularly for patients using long‐term sickness benefits prior to diagnosis. Additional study is needed to determine factors that might reduce the need for sickness benefits and enhance work ability in these patients. John Wiley and Sons Inc. 2022-05-27 2022-09 /pmc/articles/PMC9541357/ /pubmed/35621269 http://dx.doi.org/10.1111/ecc.13626 Text en © 2022 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Altena, Renske
Gernaat, Sofie A. M.
Wilking, Ulla
Kiani, Narsis A.
Johnsson, Aina
Hedayati, Elham
Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study
title Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study
title_full Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study
title_fullStr Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study
title_full_unstemmed Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study
title_short Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study
title_sort use of sickness benefits by patients with metastatic breast cancer—a swedish cohort study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541357/
https://www.ncbi.nlm.nih.gov/pubmed/35621269
http://dx.doi.org/10.1111/ecc.13626
work_keys_str_mv AT altenarenske useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy
AT gernaatsofieam useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy
AT wilkingulla useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy
AT kianinarsisa useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy
AT johnssonaina useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy
AT hedayatielham useofsicknessbenefitsbypatientswithmetastaticbreastcanceraswedishcohortstudy